NDAORALSOLUTION
Approved
Oct 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
JAVADIN (clonidine hydrochloride oral) by R-Pharm US is alpha-adrenoreceptors in the brain. Approved for hypertension in adult patients to lower blood pressure, hypertension. First approved in 2025.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAVADIN is a clonidine hydrochloride oral solution approved in October 2025 for hypertension in adult patients. It works by stimulating alpha-adrenoreceptors in the brain stem, reducing sympathetic outflow and decreasing peripheral resistance, heart rate, and blood pressure. Clonidine is a well-established antihypertensive mechanism repositioned as an oral solution formulation.
Growth15.7 years to LOE
Product is in launch phase with 15.8 years of patent exclusivity, indicating potential for sustained commercial investment and team expansion during competitive market entry.
Mechanism of Action
alpha-adrenoreceptors in the brain. Clonidine is not a central nervous system stimulant. Clonidine is a known antihypertensive agent. By stimulating alpha-adrenoreceptors in the brain stem, clonidine reduces sympathetic outflow from the central nervous system and decreases peripheral resistance,…
Worked on JAVADIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.